Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel in Refractory or Relapsed Follicular Lymphoma
NCT03568461Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- CAR-T Cells
- Countries
- 12
01
Overview
A Phase 2 trial of tisagenlecleucel in follicular lymphoma (FL), sponsored by Novartis. Started Nov 2018; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03568461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568461.